Microsomal activation to mutagens of antischistosomal methyl thioxanthenones and initial tests on a possibly non-mutagenic analogue.
Five methylthioxanthenone and methylbenzothiopyranoindazole analogues, including lucanthone (Miracil D), are non-mutagenic for Salmonella typhimurium but are activated to mutagens by a rat liver microsome preparation. Hydroxymethyl analogues, including hycathone (Etrenol), are mutagenic in the absence of microsomes. It seems reasonable to assume that the hydroxymethyl derivatives are the more proximal mutagens and that Salmonella is unable to carry out the hydroxylation necessary for mutagen activation. During the pase 24 years, several million patients with schistosomiasis have been treated with lucanthone, and in recent years about 700 000 persons with hycanthone. The possible long-term deleterious effects of these agents for man even now remain to be determined. Our studies indicate that particular modifications in the structure of thioxanthenones drastically alter their mutagenicity. One apparently non-mutagenic thioxanthenone has been found. A number of the less mutagenic compounds also exhibit decreased acute toxicity in the mouse while retaining appreciable antischistosomal activity, suggesting that genetic and schistosomicidal activities may be dissociated from each other.
D000818:Animals; D006900:Hydroxylation; D066298:In Vitro Techniques; D007191:Indazoles / Q000494:pharmacology; D008154:Lucanthone / Q000494:pharmacology; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D009153:Mutagens / Q000494:pharmacology*; D009249:NADP; D051381:Rats; D012486:Salmonella typhimurium / Q000187:drug effects / Q000378:metabolism; D012556:Schistosomicides / Q000494:pharmacology*; D013329:Structure-Activity Relationship; D013892:Thioxanthenes / Q000494:pharmacology*; D014158:Transcription, Genetic
D007191:Indazoles; D009153:Mutagens; D012556:Schistosomicides; D013892:Thioxanthenes; D009249:NADP; D008154:Lucanthone